Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Maria Dall'Era, MD

    SchoolUCSF School of Medicine
    Address533 Parnassus Ave, UC Hall
    San Francisco CA 94117
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine
      University of California, San FranciscoM.D.School of Medicine1997

      Collapse Overview 
      Collapse Overview
      Maria Dall’Era, M.D. is associate professor of clinical medicine in the Division of Rheumatology. Within rheumatology, her subspecialty is systemic lupus erythematosus (SLE). Dr. Dall’Era is the director of the UCSF Lupus Clinic in which she cares for > 200 patients with SLE. She has recently established an SLE Transition Clinic with Dr. Emily von Scheven with the goal of improving the process of transition between pediatric and adult care. She is also director of the Rheumatology Clinical Research Center in which she oversees the conduct of various clinical trials and observational research studies, and she is the UCSF Center Director for the Lupus Clinical Trials Consortium. Her research program is focused on three major areas: (1) the design and conduct of clinical trials of novel biologic agents for SLE and lupus nephritis, (2) a population-based SLE epidemiologic project funded by the Centers of Disease Control and Prevention and the California Department of Public Health with the goal of determining contemporary, accurate estimates of the incidence and prevalence of SLE in San Francisco County, and (3) a project in conjunction with the Lupus Nephritis Trials Network to determine the most appropriate renal outcome measures that should be utilized in lupus nephritis clinical trials.

      Dr. Dall’Era is also very involved with the education of trainees, both in the outpatient clinical arena, inpatient setting, and in the medical school. With a grant from the American College of Rheumatology’s Lupus Initiative, she created two pilot, interactive, on-line, virtual simulation SLE cases in collaboration with Dr. Michelle Lin. She incorporated novel features into the cases including a “differential diagnosis slider” in which the learner is required to re-adjust their differential diagnosis after case content is revealed. She currently has a grant from the American College of Rheumatology to develop additional interactive rheumatologic cases for the medical students using a mobile application platform. These cases will be utilized in the I3 section for the second year medical students. Lastly, Dr. Dall’Era is active in the education of practicing physicians and is the San Francisco lead for the National Health Education Program on Lupus for Healthcare Providers.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Awarded Grants
      Collapse Clinical Trials
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA. Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. J Immunol. 2016 Oct 1; 197(7):2854-63. PMID: 27534558.
        View in: PubMed
      2. Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA, Abramowicz D, de Bruxelles L, Atzeni F, Blockmans D, Danieli MG, De Clercq L, D'Cruz D, Guttierez Mdel M, Garrido Ede R, Gilboe IM, de Keyser F, Delahousse M, Espinosa G, Fiehn C, Golstein M, Guillevin L, Hirsch M, Karras A, Lang P, le Guern V, Marchal M, Marinho A, Max R, Peeters P, Petera P, Petrovic R, Quémeneur T, Raeman F, Remy P, Ravelingien I, Sarzi-Puttini P, Sangle S, Tektonidou M, de Santis LV, Vasconcelos C, Verresen L, Weiss L, Westhovens R. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015; 2(1):e000123. PMID: 26629352.
        View in: PubMed
      3. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015 Jul; 67(7):1848-57. PMID: 25777546.
        View in: PubMed
      4. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089. PMID: 26023331; PMCID: PMC4442174.
      5. Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015 May; 67(5):1305-13. PMID: 25605554.
        View in: PubMed
      6. Ashouri JF, Davis JL, Farkas A, Durack JC, Ramachandran R, Dall'Era M. A young woman with systemic lupus erythematosus and extensive mesenteric vasculitis involving small and medium vessels. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1928-33. PMID: 22933330.
        View in: PubMed
      7. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011 Sep; 23(5):454-8. PMID: 21720247.
        View in: PubMed
      8. Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, Katz PP. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1170-7. PMID: 21584946; PMCID: PMC3149719.
      9. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011 Aug; 13(4):308-16. PMID: 21584692; PMCID: PMC4400849.
      10. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7. PMID: 21080348.
        View in: PubMed
      11. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010; 12(2):R48. PMID: 20302641; PMCID: PMC2888197.
      12. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5. PMID: 20197774.
        View in: PubMed
      13. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3. PMID: 20102681.
        View in: PubMed
      14. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51. PMID: 19491915.
        View in: PubMed
      15. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. PMID: 18050206.
        View in: PubMed
      16. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum. 2007 Apr 15; 57(3):538-42. PMID: 17394185.
        View in: PubMed
      17. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80. PMID: 16896285.
        View in: PubMed
      18. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005 Dec; 64(12):1692-7. PMID: 15843451; PMCID: PMC1755300.
      19. Dall'Era M, Davis JC. Systemic lupus erythematosus. How to manage, when to refer. Postgrad Med. 2003 Nov; 114(5):31-7, 40. PMID: 14650091.
        View in: PubMed
      Maria's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP